Current status of implantable cardioverter-defibrillator therapy in heart failure

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Sudden cardiac arrest (SCA) is a primary cause of mortality in heart failure (HF) patients.
• Implantable cardioverter-defibrillators (ICDs) are the sole evidence-based intervention for survivors of life-threatening ventricular arrhythmias.
• Specific HF patient groups with ischemic and nonischemic dilated cardiomyopathy demonstrate benefit from ICD therapy for primary SCA prevention.

Purpose of the Study:

• To review the current evidence and guidelines for implantable cardioverter-defibrillator (ICD) therapy in heart failure (HF) patients.
• To summarize the role of ICDs in the primary prevention of sudden cardiac arrest (SCA) in HF.
• To highlight the integration of cardiac resynchronization therapy (CRT) in managing severe HF.

Main Methods:

• Review of randomized clinical trials (RCTs) evaluating ICD therapy in heart failure.
• Analysis of current practice guidelines regarding device-based therapy for HF.
• Synthesis of data on ICD efficacy for primary and secondary prevention of sudden cardiac arrest.

Main Results:

• RCTs confirm ICD benefit for primary prevention of SCA in selected HF patients with reduced ejection fraction.
• Cardiac resynchronization therapy (CRT) improves symptoms and survival in severe HF patients with ventricular dyssynchrony.
• ICD therapy is a cornerstone in managing patients at high risk for sudden cardiac death.

Conclusions:

• ICD therapy is recommended for primary prevention of sudden cardiac arrest in specific heart failure populations.
• Cardiac resynchronization therapy is a key device-based treatment for severe heart failure with dyssynchrony.
• This review consolidates current understanding of ICDs and CRT in heart failure management based on robust clinical evidence.